Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients

Dexamethasone and tocilizumab treatment considerably reduces the value of C-reactive protein and procalcitonin to detect secondary bacterial infections in COVID-19 patients

Abstract Background Procalcitonin (PCT) and C-reactive protein (CRP) were previously shown to have value for the detection of secondary infections in critically ill COVID-19 patients. However, since the introduction of immunomodulatory therapy, the value of these biomarkers is unclear. We investigat...

Full description

Bibliographic Details
Main Authors: Emma J. Kooistra, Miranda van Berkel, Noortje F. van Kempen, Celine R. M. van Latum, Niklas Bruse, Tim Frenzel, Maarten J. W. van den Berg, Jeroen A. Schouten, Matthijs Kox, Peter Pickkers
Format: Article
Language:English
Published: BMC 2021-08-01
Series:Critical Care
Subjects:
COVID-19
Procalcitonin
c-reactive protein
Prediction
Dexamethasone
Tocilizumab
Online Access:https://doi.org/10.1186/s13054-021-03717-z

Similar Items

Similar Items